{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:07:16Z","timestamp":1794535636597,"version":"4.9.1"},"reference-count":172,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007928","name":"Perelman School of Medicine, University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["1R01EY023557"],"award-info":[{"award-number":["1R01EY023557"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["P30 EY001583"],"award-info":[{"award-number":["P30 EY001583"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.biopha.2025.118319","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T11:18:33Z","timestamp":1752837513000},"page":"118319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Integrating neuroprotection, antioxidative effects, and precision medicine in glaucoma management with bioactive compounds"],"prefix":"10.1016","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0761-5001","authenticated-orcid":false,"given":"Yan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxmi","family":"Moksha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Salowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vrathasha","family":"Vrathasha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine-Ayan Ibrahim","family":"Aibo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Halimitabrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Di Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan M.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.biopha.2025.118319_bib1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/ajhp\/62.7.691","article-title":"Glaucoma and its treatment: a review","volume":"62","author":"Lee","year":"2005","journal-title":"Am. J. HealthSyst. Pharm."},{"issue":"11","key":"10.1016\/j.biopha.2025.118319_bib2","article-title":"Epidemiology of glaucoma: the past, present, and predictions for the future","volume":"12","author":"Allison","year":"2020","journal-title":"Cureus"},{"issue":"15","key":"10.1016\/j.biopha.2025.118319_bib3","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1056\/NEJM199304153281507","article-title":"Open-angle glaucoma","volume":"328","author":"Quigley","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.biopha.2025.118319_bib4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3390\/genes14091809","article-title":"Factors associated with large cup-to-disc ratio and blindness in the primary open-angle African American glaucoma genetics (POAAGG) study","volume":"14","author":"Mamidipaka","year":"2023","journal-title":"Genes"},{"issue":"6","key":"10.1016\/j.biopha.2025.118319_bib5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.survophthal.2009.05.001","article-title":"Understanding the importance of IOP variables in glaucoma: a systematic review","volume":"54","author":"Sultan","year":"2009","journal-title":"Surv. Ophthalmol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/1673-5374.344831","article-title":"Regulatory mechanisms of retinal ganglion cell death in normal tension glaucoma and potential therapies","volume":"18","author":"Shen","year":"2023","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.biopha.2025.118319_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-3-540-69475-5_2","article-title":"The epidemiology of glaucoma","author":"Giangiacomo","year":"2009","journal-title":"Glaucoma"},{"issue":"2","key":"10.1016\/j.biopha.2025.118319_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/0974-620X.64231","article-title":"Correlation of central corneal thickness and optic nerve head topography in patients with primary open-angle glaucoma","volume":"3","author":"Mokbel","year":"2010","journal-title":"Oman J. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118319_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2147\/JEP.S281187","article-title":"The latest drugs in development that reduce intraocular pressure in ocular hypertension and glaucoma","author":"Jayanetti","year":"2020","journal-title":"J. Exp. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/2040622313511286","article-title":"Glaucoma management: relative value and place in therapy of available drug treatments","volume":"5","author":"Sambhara","year":"2014","journal-title":"Ther. Adv. Chronic Dis."},{"issue":"7","key":"10.1016\/j.biopha.2025.118319_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020110","article-title":"Trabecular meshwork gene expression after selective laser trabeculoplasty","volume":"6","author":"Izzotti","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.biopha.2025.118319_bib12","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jcjo.2014.09.002","article-title":"Minimally invasive glaucoma surgery: current implants and future innovations","volume":"49","author":"SooHoo","year":"2014","journal-title":"Can. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118319_bib13","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.2147\/OPTH.S439457","article-title":"Alternatives to topical glaucoma medication for glaucoma management","author":"Bedrood","year":"2023","journal-title":"Clin. Ophthalmol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.survophthal.2014.06.006","article-title":"Systematic review and meta-analysis on the efficacy of selective laser trabeculoplasty in open-angle glaucoma","volume":"60","author":"Wong","year":"2015","journal-title":"Surv. Ophthalmol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0161-6420(81)35049-0","article-title":"Long-term control of adult open angle glaucoma by argon laser treatment","volume":"88","author":"Wise","year":"1981","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib16","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.4103\/0301-4738.73689","article-title":"Management of complications in glaucoma surgery","volume":"59","author":"Vijaya","year":"2011","journal-title":"Indian J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118319_bib17","doi-asserted-by":"crossref","first-page":"a017236","DOI":"10.1101\/cshperspect.a017236","article-title":"Clinical characteristics and current treatment of glaucoma","volume":"4","author":"Cohen","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118319_bib18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/bioengineering11020122","article-title":"Advancing glaucoma care: integrating artificial intelligence in diagnosis, management, and progression detection","volume":"11","author":"Zhu","year":"2024","journal-title":"Bioengineering"},{"issue":"9","key":"10.1016\/j.biopha.2025.118319_bib19","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1089\/wound.2015.0677","article-title":"Personalized medicine in ocular fibrosis: myth or future biomarkers","volume":"5","author":"Yu-Wai-Man","year":"2016","journal-title":"Adv. Wound Care"},{"key":"10.1016\/j.biopha.2025.118319_bib20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00401-016-1609-2","article-title":"Glaucoma: the retina and beyond","volume":"132","author":"Davis","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118319_bib21","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3390\/ijms21072262","article-title":"Neuroprotective strategies for retinal ganglion cell degeneration: current status and challenges ahead","volume":"21","author":"Boia","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2025.118319_bib22","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.3390\/nu12103158","article-title":"Natural products: evidence for neuroprotection to be exploited in glaucoma","volume":"12","author":"Adornetto","year":"2020","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3390\/nu14030534","article-title":"Treatment of glaucoma with natural products and their mechanism of action: an update","volume":"14","author":"Sim","year":"2022","journal-title":"Nutrients"},{"issue":"19","key":"10.1016\/j.biopha.2025.118319_bib24","doi-asserted-by":"crossref","first-page":"11375","DOI":"10.3390\/ijms231911375","article-title":"Citicoline eye drops protect trabecular meshwork cells from oxidative stress injury in a 3D in vitro glaucoma model","volume":"23","author":"Vernazza","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118319_bib25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0079-6123(08)01137-0","article-title":"Evidence of the neuroprotective role of citicoline in glaucoma patients","volume":"173","author":"Parisi","year":"2008","journal-title":"Prog. brain Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118319_bib26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/nu8040200","article-title":"Resveratrol and ophthalmic diseases","volume":"8","author":"Abu-Amero","year":"2016","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.biopha.2025.118319_bib27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0161-6420(02)01745-1","article-title":"Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma","volume":"110","author":"Quaranta","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.biopha.2025.118319_bib28","series-title":"Alpha lipoic acid: nature's ultimate antioxidant","author":"Sosin","year":"1998"},{"key":"10.1016\/j.biopha.2025.118319_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.molimm.2018.06.008","article-title":"Developments in anti-complement therapy; from disease to clinical trial","volume":"102","author":"Harris","year":"2018","journal-title":"Mol. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118319_bib30","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00061198-199708000-00010","article-title":"Brimonidine: a new alpha: 2:-adrenoreceptor agonist for glaucoma treatment","volume":"6","author":"Greenfield","year":"1997","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.biopha.2025.118319_bib31","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40266-015-0250-4","article-title":"Brinzolamide\/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension","volume":"32","author":"Greig","year":"2015","journal-title":"Drugs Aging"},{"issue":"7","key":"10.1016\/j.biopha.2025.118319_bib32","article-title":"Phase 1 safety, tolerability and pharmacokinetic study of topical ocular CB1 agonist, SBI-100 a novel prodrug of THC, in healthy volunteers","volume":"65","author":"Diep","year":"2024","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2025.118319_bib33","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1177\/11206721211008783","article-title":"Netarsudil: a new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension","volume":"31","author":"Batra","year":"2021","journal-title":"Eur. J. Ophthalmol."},{"issue":"15","key":"10.1016\/j.biopha.2025.118319_bib34","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1167\/iovs.18-24838","article-title":"\u03949-Tetrahydrocannabinol and cannabidiol differentially regulate intraocular pressure","volume":"59","author":"Miller","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2025.118319_bib35","author":"Allison","year":"2023","journal-title":"Pharmacol. Nat. Ther. Glaucoma Manag."},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib36","first-page":"215","article-title":"Ginkgo biloba extract in ophthalmic and systemic disease, with a focus on normal-tension glaucoma","volume":"9","author":"Labkovich","year":"2020","journal-title":"AsiaPac. J. Ophthalmol."},{"issue":"17","key":"10.1016\/j.biopha.2025.118319_bib37","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1055\/a-0947-5712","article-title":"Neuroprotective potential of Ginkgo biloba in retinal diseases","volume":"85","author":"Mart\u00ednez-Sol\u00eds","year":"2019","journal-title":"Planta Med."},{"issue":"12","key":"10.1016\/j.biopha.2025.118319_bib38","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1001\/archophthalmol.2008.512","article-title":"Effect of topical Ginkgo biloba extract on steroid-induced changes in the trabecular meshwork and intraocular pressure","volume":"126","author":"Jia","year":"2008","journal-title":"Arch. Ophthalmol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118319_bib39","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3390\/antiox11071268","article-title":"Ginkgo biloba extract attenuates light-induced photoreceptor degeneration by modulating CAV-1\u2014redoxosome signaling","volume":"11","author":"Wang","year":"2022","journal-title":"Antioxidants"},{"issue":"06","key":"10.1016\/j.biopha.2025.118319_bib40","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1055\/a-1109-3405","article-title":"Effects of Ginkgo biloba on diseases related to oxidative stress","volume":"86","author":"de Souza","year":"2020","journal-title":"Planta Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118319_bib41","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1179\/1351000212Y.0000000033","article-title":"Oxidative stress and potential applications of free radical scavengers in glaucoma","volume":"18","author":"Aslan","year":"2013","journal-title":"Redox Rep."},{"issue":"15","key":"10.1016\/j.biopha.2025.118319_bib42","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.64.15.28","article-title":"Resveratrol alleviates retinal ischemia-reperfusion injury by inhibiting the NLRP3\/gasdermin D\/Caspase-1\/Interleukin-1\u03b2 pyroptosis pathway","volume":"64","author":"Xie","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2025.118319_bib43","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1167\/iovs.18-24539","article-title":"Effect of resveratrol on sirtuins, OPA1, and Fis1 expression in adult zebrafish retina","volume":"59","author":"Sheng","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2025.118319_bib44","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00417-014-2604-8","article-title":"Resveratrol and the eye: activity and molecular mechanisms","volume":"252","author":"Bola","year":"2014","journal-title":"Graefe'S. Arch. Clin. Exp. Ophthalmol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib45","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/ceo.12375","article-title":"Role of adenosine receptors in resveratrol-induced intraocular pressure lowering in rats with steroid-induced ocular hypertension","volume":"43","author":"Razali","year":"2015","journal-title":"Clin. Exp. Ophthalmol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118319_bib46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5114\/ceji.2019.87070","article-title":"Therapeutic potential of curcumin in eye diseases","volume":"44","author":"Radomska-Le\u015bniewska","year":"2019","journal-title":"Cent. Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118319_bib47","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00417-021-05542-0","article-title":"Role of curcumin in retinal diseases\u2014a review","volume":"260","author":"Chandrasekaran","year":"2022","journal-title":"Graefe'S. Arch. Clin. Exp. Ophthalmol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118319_bib48","article-title":"Curcumin inhibits neuronal and vascular degeneration in retina after ischemia and reperfusion injury","volume":"6","author":"Wang","year":"2011","journal-title":"PloS One"},{"issue":"04","key":"10.1016\/j.biopha.2025.118319_bib49","first-page":"249","article-title":"Curcumin: therapeutical potential in ophthalmology","volume":"80","author":"Pescosolido","year":"2014","journal-title":"Planta Med."},{"key":"10.1016\/j.biopha.2025.118319_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.893118","article-title":"Mechanisms underlying curcumin-induced neuroprotection in cerebral ischemia","volume":"13","author":"Fan","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118319_bib51","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11655-015-2159-5","article-title":"Curcumin reduces cardiac fibrosis by inhibiting myofibroblast differentiation and decreasing transforming growth factor \u03b21 and matrix metalloproteinase 9\/tissue inhibitor of metalloproteinase 1","volume":"23","author":"Ma","year":"2017","journal-title":"Chin. J. Integr. Med."},{"key":"10.1016\/j.biopha.2025.118319_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.585413","article-title":"Toward regulatory effects of curcumin on transforming growth factor-beta across different diseases: a review","volume":"11","author":"Ashrafizadeh","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib53","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40662-022-00298-y","article-title":"Nanoparticles for the treatment of glaucoma-associated neuroinflammation","volume":"9","author":"Lambuk","year":"2022","journal-title":"Eye Vis."},{"issue":"2","key":"10.1016\/j.biopha.2025.118319_bib54","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/17469899.2019.1604222","article-title":"Neuroprotection in glaucoma: old concepts, new ideas","volume":"14","author":"Shamsher","year":"2019","journal-title":"Expert Rev. Ophthalmol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118319_bib55","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.3390\/jcm9123978","article-title":"Cannabinoids in glaucoma patients: the never-ending story","volume":"9","author":"Passani","year":"2020","journal-title":"J. Clin. Med."},{"issue":"8","key":"10.1016\/j.biopha.2025.118319_bib56","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3390\/ph16081149","article-title":"Therapeutic potential of cannabinoids in glaucoma","volume":"16","author":"Lindner","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"7","key":"10.1016\/j.biopha.2025.118319_bib57","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2174\/1570159X15666170724104305","article-title":"Neuroprotection by (endo) cannabinoids in glaucoma and retinal neurodegenerative diseases","volume":"16","author":"Rapino","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.biopha.2025.118319_bib58","unstructured":"Aref, A.A. and M.Tala Al-Khaled, Cannabinoids for Glaucoma."},{"issue":"7","key":"10.1016\/j.biopha.2025.118319_bib59","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.3390\/ijms22073798","article-title":"Cannabidiol and the canonical WNT\/\u03b2-catenin pathway in glaucoma","volume":"22","author":"Vall\u00e9e","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118319_bib60","doi-asserted-by":"crossref","DOI":"10.15273\/dmj.Vol46No1.9830","article-title":"Cannabis and glaucoma: a literature review","author":"MacMillan","year":"2019","journal-title":"Dalhous. Med. J."},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib61","first-page":"5369797","article-title":"Therapeutic effects of the combination of alpha-lipoic acid (ala) and coenzyme Q10 (CoQ10) on cisplatin-induced nephrotoxicity","volume":"2020","author":"Khalifa","year":"2020","journal-title":"Int. J. Inflamm."},{"issue":"4","key":"10.1016\/j.biopha.2025.118319_bib62","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/antiox8040096","article-title":"Water-and fat-soluble antioxidants in human seminal plasma and serum of fertile males","volume":"8","author":"Lazzarino","year":"2019","journal-title":"Antioxidants"},{"issue":"7","key":"10.1016\/j.biopha.2025.118319_bib63","first-page":"38","article-title":"A spotlight on ALA: alpha lipoic acid may be important to neurological and vascular conditions, including diabetes","volume":"146","author":"Chous","year":"2009","journal-title":"Rev. Optom."},{"issue":"6","key":"10.1016\/j.biopha.2025.118319_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065389","article-title":"\u03b1-Lipoic acid antioxidant treatment limits glaucoma-related retinal ganglion cell death and dysfunction","volume":"8","author":"Inman","year":"2013","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib65","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.oftal.2019.11.009","article-title":"Effect of an oral supplementation with a formula containing R-lipoic acid in glaucoma patients","volume":"95","author":"Sanz-Gonz\u00e1lez","year":"2020","journal-title":"Arch. De. la Soc. Espa\u00f1ola De. Oftalmol. \u00eda (Engl. Ed. )"},{"issue":"6","key":"10.1016\/j.biopha.2025.118319_bib66","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.2337\/diabetes.50.6.1464","article-title":"The antihyperglycemic drug \u03b1-lipoic acid stimulates glucose uptake via both GLUT4 translocation and GLUT4 activation: potential role of p38 mitogen-activated protein kinase in GLUT4 activation","volume":"50","author":"Konrad","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2025.118319_bib67","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00011-017-1079-6","article-title":"Biochemical and clinical relevance of alpha lipoic acid: antioxidant and anti-inflammatory activity, molecular pathways and therapeutic potential","volume":"66","author":"Tibullo","year":"2017","journal-title":"Inflamm. Res."},{"issue":"9","key":"10.1016\/j.biopha.2025.118319_bib68","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1089\/jmf.2012.2241","article-title":"Ginkgo biloba extract and bilberry anthocyanins improve visual function in patients with normal tension glaucoma","volume":"15","author":"Shim","year":"2012","journal-title":"J. Med. Food"},{"key":"10.1016\/j.biopha.2025.118319_bib69","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2147\/OPTH.S145159","article-title":"Bilberry extract administration prevents retinal ganglion cell death in mice via the regulation of chaperone molecules under conditions of endoplasmic reticulum stress","author":"Nakamura","year":"2017","journal-title":"Clin. Ophthalmol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib70","first-page":"9539681","article-title":"Cytoprotective effect of astaxanthin in a model of normal intraocular pressure glaucoma","volume":"2020","author":"Kikuchi","year":"2020","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118319_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchemneu.2020.101876","article-title":"Astaxanthin protects retinal ganglion cells from acute glaucoma via the Nrf2\/HO-1 pathway","volume":"110","author":"Li","year":"2020","journal-title":"J. Chem. Neuroanat."},{"issue":"7","key":"10.1016\/j.biopha.2025.118319_bib72","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/antiox12071320","article-title":"Green tea catechins as therapeutic antioxidants for glaucoma treatment","volume":"12","author":"Ng","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.biopha.2025.118319_bib73","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fnins.2019.00672","article-title":"Quercetin enhances inhibitory synaptic inputs and reduces excitatory synaptic inputs to OFF-and ON-type retinal ganglion cells in a chronic glaucoma rat model","volume":"13","author":"Zhou","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.biopha.2025.118319_bib74","series-title":"Handbook of Nutrition, Diet, and the Eye","first-page":"189","article-title":"Quercetin and Glaucoma","author":"Miyamoto","year":"2019"},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jgr.2018.11.006","article-title":"Ginseng for an eye: effects of ginseng on ocular diseases","volume":"44","author":"Kim","year":"2020","journal-title":"J. Ginseng Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib76","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5142\/jgr.2010.34.3.237","article-title":"Effect of Korean red ginseng supplementation on ocular blood flow in patients with glaucoma","volume":"34","author":"Kim","year":"2010","journal-title":"J. Ginseng Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jgr.2014.07.002","article-title":"Effect of Korean Red Ginseng supplementation on dry eye syndrome in glaucoma patients\u2013a randomized, double-blind, placebo-controlled study","volume":"39","author":"Bae","year":"2015","journal-title":"J. Ginseng Res."},{"key":"10.1016\/j.biopha.2025.118319_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6882-14-399","article-title":"The ocular hypotensive effect of saffron extract in primary open angle glaucoma: a pilot study","volume":"14","author":"Jabbarpoor Bonyadi","year":"2014","journal-title":"BMC Complement. Altern. Med."},{"issue":"17","key":"10.1016\/j.biopha.2025.118319_bib79","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.3390\/ijms20174110","article-title":"Neuroprotective and anti-inflammatory effects of a hydrophilic saffron extract in a model of glaucoma","volume":"20","author":"Fern\u00e1ndez-Albarral","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118319_bib80","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.exer.2017.12.005","article-title":"Omega-3 fatty acids protect retinal neurons in the DBA\/2J hereditary glaucoma mouse model","volume":"167","author":"Kalogerou","year":"2018","journal-title":"Exp. eye Res."},{"key":"10.1016\/j.biopha.2025.118319_bib81","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2147\/OPTH.S96433","article-title":"Omega-3 fatty acid supplementation improves dry eye symptoms in patients with glaucoma: results of a prospective multicenter study","author":"Tellez-Vazquez","year":"2016","journal-title":"Clin. Ophthalmol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118319_bib82","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3109\/1061186X.2016.1157883","article-title":"Oral bioavailability of curcumin: problems and advancements","volume":"24","author":"Liu","year":"2016","journal-title":"J. Drug Target."},{"issue":"6","key":"10.1016\/j.biopha.2025.118319_bib83","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3390\/ijms20061381","article-title":"Progress to improve oral bioavailability and beneficial effects of resveratrol","volume":"20","author":"Chimento","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118319_bib84","series-title":"in Pharmaceutical Calibration, Validation and Qualification: A Comprehensive Approach","first-page":"187","article-title":"Approach for Herbal Standardization","author":"Shukla","year":"2023"},{"issue":"2","key":"10.1016\/j.biopha.2025.118319_bib85","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3934\/molsci.2024010","article-title":"Bioactive compounds from plants and by-products: novel extraction methods, applications, and limitations","volume":"11","author":"Zaky","year":"2024","journal-title":"AIMS Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2025.118319_bib86","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4103\/2008-322X.183923","article-title":"Neuroprotection in glaucoma","volume":"11","author":"Doozandeh","year":"2016","journal-title":"J. Ophthalmic Vis. Res."},{"issue":"5","key":"10.1016\/j.biopha.2025.118319_bib87","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s41433-018-0050-2","article-title":"Neuroprotective agents in the management of glaucoma","volume":"32","author":"Nucci","year":"2018","journal-title":"Eye"},{"key":"10.1016\/j.biopha.2025.118319_bib88","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/00003495-200767050-00006","article-title":"Pharmacological neuroprotection for glaucoma","volume":"67","author":"Chidlow","year":"2007","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.biopha.2025.118319_bib89","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.ophtha.2018.06.017","article-title":"Oral memantine for the treatment of glaucoma: design and results of 2 randomized, placebo-controlled, phase 3 studies","volume":"125","author":"Weinreb","year":"2018","journal-title":"Ophthalmology"},{"issue":"2_","key":"10.1016\/j.biopha.2025.118319_bib90","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/112067210101102S03","article-title":"Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma","volume":"11","author":"Wheeler","year":"2001","journal-title":"Eur. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118319_bib91","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ajo.2010.09.026","article-title":"A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study","volume":"151","author":"Krupin","year":"2011","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118319_bib92","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s12325-020-01277-2","article-title":"Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma: pooled efficacy\/safety analysis of phase 3 MERCURY-1 and-2","volume":"37","author":"Asrani","year":"2020","journal-title":"Adv. Ther."},{"issue":"11","key":"10.1016\/j.biopha.2025.118319_bib93","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.ophtha.2018.04.040","article-title":"Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension","volume":"125","author":"Tanna","year":"2018","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.biopha.2025.118319_bib94","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00417-022-05947-5","article-title":"The effect of citicoline oral solution on quality of life in patients with glaucoma: the results of an international, multicenter, randomized, placebo-controlled cross-over trial","volume":"261","author":"Rossetti","year":"2023","journal-title":"Graefe'S. Arch. Clin. Exp. Ophthalmol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118319_bib95","doi-asserted-by":"crossref","first-page":"28401","DOI":"10.3390\/ijms161226099","article-title":"Cytidine 5\u2032-diphosphocholine (citicoline) in glaucoma: rationale of its use, current evidence and future perspectives","volume":"16","author":"Roberti","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118319_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/genes15060786","article-title":"Study on genotypes and phenotypes of neurodegenerative diseases","author":"Ricci","year":"2024","journal-title":"Genes"},{"issue":"9","key":"10.1016\/j.biopha.2025.118319_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0291836","article-title":"Efficacy of citicoline as a supplement in glaucoma patients: a systematic review","volume":"18","author":"Prinz","year":"2023","journal-title":"Plos One"},{"key":"10.1016\/j.biopha.2025.118319_bib98","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.nbd.2016.08.004","article-title":"Neurotrophin receptor agonists and antagonists as therapeutic agents: an evolving paradigm","volume":"97","author":"Josephy-Hernandez","year":"2017","journal-title":"Neurobiol. Dis."},{"issue":"5","key":"10.1016\/j.biopha.2025.118319_bib99","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1172\/JCI41356","article-title":"Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents","volume":"120","author":"Massa","year":"2010","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100298","article-title":"Phase I NT-501 ciliary neurotrophic factor implant trial for primary open-angle glaucoma: safety, neuroprotection, and neuroenhancement","volume":"3","author":"Goldberg","year":"2023","journal-title":"Ophthalmol. Sci."},{"key":"10.1016\/j.biopha.2025.118319_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.875662","article-title":"Brain-derived neurotrophic factor-mediated neuroprotection in glaucoma: a review of current state of the art","volume":"13","author":"Lambuk","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib102","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/15321819.2020.1726774","article-title":"Biomarkers of inflammation and oxidative stress in ophthalmic disorders","volume":"41","author":"Ahmad","year":"2020","journal-title":"J. Immunoass. Immunochem."},{"issue":"2","key":"10.1016\/j.biopha.2025.118319_bib103","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/nu11020239","article-title":"Substances of interest that support glaucoma therapy","volume":"11","author":"Sacc\u00e0","year":"2019","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib104","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2174\/1874467212666181127151059","article-title":"Mitochondria-targeted drugs","volume":"12","author":"Zinovkin","year":"2019","journal-title":"Curr. Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib105","doi-asserted-by":"crossref","first-page":"7469326","DOI":"10.1155\/2016\/7469326","article-title":"Nrf2 is an attractive therapeutic target for retinal diseases","volume":"2016","author":"Nakagami","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.biopha.2025.118319_bib106","first-page":"1149","article-title":"Role of Nrf2 in disease: novel molecular mechanisms and therapeutic approaches","author":"Egea","year":"2019","journal-title":"Front. Media SA"},{"key":"10.1016\/j.biopha.2025.118319_bib107","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00002018-200225040-00002","article-title":"Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review","volume":"25","author":"Gaynes","year":"2002","journal-title":"Drug Saf."},{"issue":"4","key":"10.1016\/j.biopha.2025.118319_bib108","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/life13041018","article-title":"Glaucoma and systemic disease","volume":"13","author":"Hsu","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.biopha.2025.118319_bib109","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0079-6123(08)01128-X","article-title":"TNF-\u03b1 signaling in glaucomatous neurodegeneration","volume":"173","author":"Tezel","year":"2008","journal-title":"Prog. brain Res."},{"key":"10.1016\/j.biopha.2025.118319_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.740057","article-title":"TNF-\u03b1 in uveitis: from bench to clinic","volume":"12","author":"Jiang","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib111","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4103\/1673-5374.179053","article-title":"Neuroinflammation in glaucoma: soluble tumor necrosis factor alpha and the connection with excitotoxic damage","volume":"11","author":"Vargas","year":"2016","journal-title":"Neural Regen. Res."},{"issue":"12","key":"10.1016\/j.biopha.2025.118319_bib112","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1089\/neu.2019.6725","article-title":"Modulation of post-traumatic immune response using the IL-1 receptor antagonist anakinra for improved visual outcomes","volume":"37","author":"Evans","year":"2020","journal-title":"J. Neurotrauma"},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib113","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0002-9394(98)00095-6","article-title":"and T.B.P.T.S. Group, Clinical efficacy and safety of brinzolamide (Azopt\u2122), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension.","volume":"126","author":"Silver","year":"1998","journal-title":"Am. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib114","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2147\/OPTH.S3182","article-title":"Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension","volume":"2","author":"Iester","year":"2008","journal-title":"Clin. Ophthalmol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118319_bib115","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ophtha.2016.01.019","article-title":"Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study","volume":"123","author":"Weinreb","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.biopha.2025.118319_bib116","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.2147\/OPTH.S103985","article-title":"Critical evaluation of latanoprostene bunod in the treatment of glaucoma","author":"Garcia","year":"2016","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118319_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118072","article-title":"Sunitinib-induced oxidative imbalance and retinotoxic effects in rats","volume":"257","author":"Santana-Garrido","year":"2020","journal-title":"Life Sci."},{"issue":"10","key":"10.1016\/j.biopha.2025.118319_bib118","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1136\/bjo.2005.067637","article-title":"Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension","volume":"89","author":"Fuchsj\u00e4ger-Mayrl","year":"2005","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118319_bib119","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2165\/00002512-199710050-00006","article-title":"Dorzolamide: a review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension","volume":"10","author":"Balfour","year":"1997","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib120","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1089\/jop.1999.15.189","article-title":"Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma","volume":"15","author":"Harris","year":"1999","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2025.118319_bib121","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archophthalmol.2008.595","article-title":"Reduction of intraocular pressure with anecortave acetate in eyes with ocular steroid injection\u2013related glaucoma","volume":"127","author":"Robin","year":"2009","journal-title":"Arch. Ophthalmol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118319_bib122","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1345\/aph.1R229","article-title":"Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension","volume":"46","author":"Swymer","year":"2012","journal-title":"Ann. Pharmacother."},{"issue":"15","key":"10.1016\/j.biopha.2025.118319_bib123","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1517\/14656566.2011.606810","article-title":"Tafluprost for glaucoma","volume":"12","author":"Papadia","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"issue":"12","key":"10.1016\/j.biopha.2025.118319_bib124","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/eye.2017.125","article-title":"Real-world experience with 0.2 \u03bcg\/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom","volume":"31","author":"Bailey","year":"2017","journal-title":"Eye"},{"key":"10.1016\/j.biopha.2025.118319_bib125","first-page":"1","article-title":"Socioeconomic and environmental factors associated with glaucoma in an African Ancestry Population: findings from the Primary Open-Angle African American Glaucoma Genetics (POAAGG) study","author":"Mamidipaka","year":"2024","journal-title":"Eye"},{"key":"10.1016\/j.biopha.2025.118319_bib126","first-page":"883","article-title":"An emerging treatment option for glaucoma: rho kinase inhibitors","author":"Wang","year":"2014","journal-title":"Clin. Ophthalmol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib127","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10792-021-02002-w","article-title":"Status of Rho kinase inhibitors in glaucoma therapeutics\u2014an overview","volume":"42","author":"Saha","year":"2022","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118319_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101225","article-title":"Novel frontiers in neuroprotective therapies in glaucoma: molecular and clinical aspects","volume":"94","author":"Boccaccini","year":"2023","journal-title":"Mol. Asp. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib129","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-statistics-030718-105251","article-title":"Precision medicine","volume":"6","author":"Kosorok","year":"2019","journal-title":"Annu. Rev. Stat. Appl."},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib130","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/02713683.2019.1663385","article-title":"Neuroprotection in glaucoma: towards clinical trials and precision medicine","volume":"45","author":"Khatib","year":"2020","journal-title":"Curr. Eye Res."},{"issue":"R1","key":"10.1016\/j.biopha.2025.118319_bib131","doi-asserted-by":"crossref","first-page":"R21","DOI":"10.1093\/hmg\/ddx184","article-title":"Genetics of glaucoma","volume":"26","author":"Wiggs","year":"2017","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.biopha.2025.118319_bib132","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/vision8020024","article-title":"Features associated with visible lamina cribrosa pores in individuals of african ancestry with glaucoma: primary open-angle african ancestry glaucoma genetics (POAAGG) study","volume":"8","author":"Jordan","year":"2024","journal-title":"Vision"},{"issue":"4","key":"10.1016\/j.biopha.2025.118319_bib133","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/bjo.64.4.227","article-title":"Genetic markers in glaucoma","volume":"64","author":"David","year":"1980","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118319_bib134","first-page":"79","article-title":"Genetic markers in primary open-angle glaucoma","volume":"20","author":"Abecia","year":"1996","journal-title":"Int. Ophthalmol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib135","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/jama.1991.03470030069026","article-title":"Racial variations in the prevalence of primary open-angle glaucoma: the Baltimore Eye Survey","volume":"266","author":"Tielsch","year":"1991","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.biopha.2025.118319_bib136","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.cell.2023.12.006","article-title":"A multi-cohort genome-wide association study in African ancestry individuals reveals risk loci for primary open-angle glaucoma","volume":"187","author":"Verma","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib137","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s11658-024-00600-x","article-title":"APOE2 protects against A\u03b2 pathology by improving neuronal mitochondrial function through ERR\u03b1 signaling","volume":"29","author":"Ning","year":"2024","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib138","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13024-022-00574-4","article-title":"ApoE in Alzheimer\u2019s disease: pathophysiology and therapeutic strategies","volume":"17","author":"Raulin","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.biopha.2025.118319_bib139","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00002512-200320080-00005","article-title":"Latanoprost: an update of its use in glaucoma and ocular hypertension","volume":"20","author":"Perry","year":"2003","journal-title":"Drugs Aging"},{"issue":"2","key":"10.1016\/j.biopha.2025.118319_bib140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000225963","article-title":"Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost","volume":"42","author":"Cheng","year":"2009","journal-title":"Ophthalmic Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoint.2024.100053","article-title":"Optic cup morphology associated with glaucomatous damage: findings from the primary open-angle African American glaucoma genetics (POAAGG) study","volume":"1","author":"Mamidipaka","year":"2024","journal-title":"AJO Int."},{"key":"10.1016\/j.biopha.2025.118319_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.06.003","article-title":"Cholinergic nervous system and glaucoma: from basic science to clinical applications","volume":"72","author":"Faiq","year":"2019","journal-title":"Prog. Retin. eye Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib143","doi-asserted-by":"crossref","first-page":"42","DOI":"10.55544\/jrasb.1.3.6","article-title":"Bioactive herbal medicine use for eye sight: a meta analysis","volume":"1","author":"Amle","year":"2022","journal-title":"J. Res. Appl. Sci. Biotechnol."},{"key":"10.1016\/j.biopha.2025.118319_bib144","series-title":"Handbook of cannabis and related pathologies","first-page":"813","article-title":"Cannabinoids as potent inhibitors of human CYP1 enzymes","author":"Watanabe","year":"2017"},{"key":"10.1016\/j.biopha.2025.118319_bib145","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.612422","article-title":"The role of neuroinflammation in glaucoma: an update on molecular mechanisms and new therapeutic options","volume":"11","author":"Rolle","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.biopha.2025.118319_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2020.104023","article-title":"Nrf-2 activator sulforaphane protects retinal cells from oxidative stress-induced retinal injury","volume":"71","author":"Chang","year":"2020","journal-title":"J. Funct. Foods"},{"issue":"6","key":"10.1016\/j.biopha.2025.118319_bib147","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1016\/j.survophthal.2007.08.011","article-title":"What are the biomarkers for glaucoma?","volume":"52","author":"Golubnitschaja","year":"2007","journal-title":"Surv. Ophthalmol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib148","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1167\/iovs.18-24878","article-title":"Identification of candidate miRNA biomarkers for glaucoma","volume":"60","author":"Hindle","year":"2019","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib149","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0002-9394(03)00792-X","article-title":"Optical coherence tomography to detect and manage retinal disease and glaucoma","volume":"137","author":"Jaffe","year":"2004","journal-title":"Am. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118319_bib150","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0002-9394(99)80183-4","article-title":"Mapping structural to functional damage in glaucoma with standard automated perimetry and confocal scanning laser ophthalmoscopy","volume":"125","author":"Anton","year":"1998","journal-title":"Am. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib151","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/jpm9030040","article-title":"Pharmacogenomic testing: clinical evidence and implementation challenges","volume":"9","author":"Hippman","year":"2019","journal-title":"J. Pers. Med."},{"issue":"7","key":"10.1016\/j.biopha.2025.118319_bib152","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/jamaophthalmol.2015.0980","article-title":"Occurrence of CYP1B1 mutations in juvenile open-angle glaucoma with advanced visual field loss","volume":"133","author":"Souzeau","year":"2015","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118319_bib153","series-title":"Recommendations for Genetic Testing of Inherited Eye Diseases","author":"Stone","year":"2014"},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2005.06.028","article-title":"The glaucoma research foundation patient survey: patient understanding of glaucoma and its treatment","volume":"141","author":"Herndon","year":"2006","journal-title":"Am. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib155","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/ijms19010102","article-title":"Alpha lipoic acid: a therapeutic strategy that tend to limit the action of free radicals in transplantation","volume":"19","author":"Ambrosi","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.biopha.2025.118319_bib156","doi-asserted-by":"crossref","first-page":"9015","DOI":"10.3390\/app10249015","article-title":"Neurotrophic factors in glaucoma and innovative delivery systems","volume":"10","author":"Mallone","year":"2020","journal-title":"Appl. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2025.118319_bib157","article-title":"Recombinant human nerve growth factor (rhNGF) eye drops for glaucoma: Results from a prospective double-masked randomized controlled trial","volume":"60","author":"Nunez","year":"2019","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2025.118319_bib158","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/ceo.13818","article-title":"Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial","volume":"48","author":"Hui","year":"2020","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118319_bib159","first-page":"390","article-title":"Ginkgo biloba: an adjuvant therapy for progressive normal and high tension glaucoma","volume":"18","author":"Cybulska-Heinrich","year":"2012","journal-title":"Mol. Vis."},{"issue":"23","key":"10.1016\/j.biopha.2025.118319_bib160","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.2174\/138161209788923886","article-title":"Nanocarriers in ocular drug delivery: an update review","volume":"15","author":"Wadhwa","year":"2009","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib161","first-page":"390","article-title":"Nanoparticles in the ocular drug delivery","volume":"6","author":"Zhou","year":"2013","journal-title":"Int. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118319_bib162","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118319_bib163","doi-asserted-by":"crossref","first-page":"1421959","DOI":"10.3389\/fmolb.2024.1421959","article-title":"Lipid-based nanoparticles: innovations in ocular drug delivery","volume":"11","author":"Baig","year":"2024","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib164","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jcis.2011.04.006","article-title":"Curcumin-loaded biocompatible thermoresponsive polymeric nanoparticles for cancer drug delivery","volume":"360","author":"Rejinold","year":"2011","journal-title":"J. Colloid Interface Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118319_bib165","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3390\/molecules30030457","article-title":"Curcumin in ophthalmology: mechanisms, challenges, and emerging opportunities","volume":"30","author":"Ribeiro","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2025.118319_bib166","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2024.05.031","article-title":"In situ gelling systems for ocular drug delivery","volume":"371","author":"Ahmed","year":"2024","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.biopha.2025.118319_bib167","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3390\/pharmaceutics16111398","article-title":"Revolutionizing eye care: exploring the potential of microneedle drug delivery","volume":"16","author":"Rojekar","year":"2024","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.biopha.2025.118319_bib168","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.drudis.2019.05.031","article-title":"Recent advances in intraocular sustained-release drug delivery devices","volume":"24","author":"Cao","year":"2019","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.biopha.2025.118319_bib169","first-page":"17","article-title":"Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: a review of the literature","volume":"9","author":"Conant","year":"2004","journal-title":"Altern. Med. Rev."},{"key":"10.1016\/j.biopha.2025.118319_bib170","doi-asserted-by":"crossref","first-page":"1020993","DOI":"10.3389\/fmed.2022.1020993","article-title":"Combined use of coenzyme Q10 and citicoline: a new possibility for patients with glaucoma","volume":"9","author":"Martucci","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.biopha.2025.118319_bib171","first-page":"471","article-title":"Mirtogenol\u00ae potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects","author":"Steigerwalt","year":"2010","journal-title":"Clin. Ophthalmol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118319_bib172","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.drudis.2019.03.022","article-title":"Combination therapy and co-delivery strategies to optimize treatment of posterior segment neurodegenerative diseases","volume":"24","author":"Arranz-Romera","year":"2019","journal-title":"Drug Discov. Today"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500513X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500513X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:38:59Z","timestamp":1778693939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222500513X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":172,"alternative-id":["S075333222500513X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118319","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating neuroprotection, antioxidative effects, and precision medicine in glaucoma management with bioactive compounds","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118319"}}